Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Abstract Background Treatment with brexucabtagene autoleucel (brexu-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated a high objective response rate (93%) and complete response rate (67%) in 60 patients with relapsed/refractory mantle cell lymphoma (R/R MCL)...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Javier Muñoz, Frederick L. Locke, Patrick M. Reagan, Andre Goy, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Wangshu Zhang, Rhine R. Shen, Rita Damico Khalid, Ioana Kloos, Michael L. Wang
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	BMC 2026-04-01
Seri Bilgileri:	Journal of Hematology & Oncology
Konular:	Brexu-cel CAR T-cell therapy Mantle cell lymphoma ZUMA-2 Long-term follow-up
Online Erişim:	https://doi.org/10.1186/s13045-026-01797-4
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2

Benzer Materyaller